Cited by 34Neuroblastoma Research and TreatmentsRNA Research and SplicingGenetics and Neurodevelopmental Disorders

HuD, a neuronal-specific RNA-binding protein, is a potential regulator of MYCN expression in human neuroblastoma cells

Ross, R.A, Lazarova, D.L, Manley, G.T, Smitt, P.S, Spengler, B.A, Posner, J.B, Biedler, J.L·1997·European Journal of Cancer

Abstract

HuD is one of a family of neural antigens recognised by the sera of patients with antibody-associated paraneoplastic encephalomyelitis. Localised exclusively to neurons, these proteins are among the earliest markers of the developing nervous system. Sequence analysis suggests that HuD is an RNA-binding protein. Hu protein levels were determined for the three cell types characterising human neuroblastoma cell lines: sympathoadrenal neuroblasts (N), substrate-adherent Schwann/glial/melanoblastic precursors (S) and stem cells (I) which can give rise to both N and S cells. Western blot analysis showed similar levels of protein in three N-type cell lines; S cells have no detectable Hu protein. Northern blot analysis indicated that N cells express all three Hu genes, HuD, HuC and Hel-N1. N cells, mostly from MYCN-amplified cell lines, have consistently higher steady-state levels of MYCN mRNA than S cell counterparts. Nuclear run-on and mRNA half-life experiments revealed no differences in transcription rate or mRNA stability between N and S cells from the LA-N-1 cell line, implicating differences in post-transcriptional regulation. HuD is postulated to be instrumental in splicing/processing and/or stabilisation of mRNAs involved in cell growth and neuronal differentiation. As determined by gel-mobility shift assays, HuD fusion protein binds to the 3'UTR of human MYCN mRNA. Analysis of HuD deletion mutants has demonstrated that the first and second RNA-recognition motifs (RRMs) are…

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(97)00331-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The first two RRMs of HuD bind to cis-acting elements, typically in the 3′ UTR, while the third RRM interacts with the poly(A) tail of transcripts and stabilizes the RBP-mRNA complex.

    “Deletion and mutational analysis of the HuD protein revealed that the first two RRMs bind to the cis-acting elements, typically in the 3′ UTR, while the third RRM interacts with the poly(A) tail of transcripts and stabilizes the RBP-mRNA complex (Chung et al. 1996, 1997; Ma et al. 1997; Ross et al. 1997; Anderson et al. 2000; Park et al. 2000; Wang and Tanaka Hall 2001; Beckel-Mitchener et al. 200”
  • HuD binds short-lived mRNAs whose protein product functions in cell proliferation, such as N-myc and c-myc.

    “Numerous other ARE-harboring transcripts, such as N-myc and c-myc, were later identified as targets of HuD using similar in vitro approaches, indicating that HuD binds short-lived mRNAs whose protein product functions in cell proliferation (Liu et al. 1995; Ross et al. 1997).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ross, R. A., Lazarova, D. L., Manley, G. T., Smitt, P. S., Spengler, B. A., Posner, J. B., & Biedler, J. L.
Affiliations
  • Fordham University (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Ross, R.A
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
1997-10
Volume
33
Issue
12
Pages
2071-2074
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2009087469
Cited by
34
References
1
Citations by year
2026: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2013: 3 · 2012: 2
FWCI
0.85
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ca041520-07)
  • National Cancer Institute (CA-41520)
  • National Institute of Neurological Disorders and Stroke (NS 2604)
Topics
  • Health Sciences › Medicine › Neurology › Neuroblastoma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
HUD, RNA-binding proteins, MYCN, neuroblastoma, post-transcriptional regulation, 3' untranslated region, RNA recognition motif, mRNA stability, HuC, neuronal differentiation, MYCN amplification, tumor aggressiveness
MeSH terms
ELAV-Like Protein 4, Binding Sites, Humans, Neoplasm Proteins, Nerve Tissue Proteins, Neuroblastoma, Protein Binding, RNA, Messenger, Tumor Cells, Cultured, Blotting, Northern, Proto-Oncogene Proteins c-myc, RNA-Binding Proteins, Sequence Deletion, ELAV Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review